Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool December 21, 2004 Brian Gorman	Pfizer Won't Let Go Pfizer is hoping that Celebrex will survive in some form. But the pharmaceutical giant has also determined that the drug should no longer be advertised to consumers. Its shares were pounded again following its revelation that it would pull such ads.
The Motley Fool October 8, 2004 Whitney Tilson	Blue-Chip Bargains? Sifting through beaten-down stocks may yield some good investments. But be careful, most of these stocks are that way for a reason.
The Motley Fool May 27, 2005 Nick Baker	Mama Always Said You'd Go Blind Urban legends aside, what do new concerns about Viagra and Cialis mean for investors?
The Motley Fool October 7, 2004 Brian Gorman	Pfizer Will Weather the Storm The company will likely come out on top regardless of the outcome of the latest controversies. Pfizer remains a quality choice for long-term investors.
Registered Rep. March 1, 2005 David A. Twibell	What Ails You? Investors who are wary of big pharma investments have good reasons to be. But this does not mean that the sector is to be avoided at all costs. Indeed, for savvy, well-informed investors, now might be a good time to jump in.
BusinessWeek November 29, 2004 Catherine Arnst	Big Pharma's Blinders Hugely profitable thanks to a few blockbusters, Big Pharma is far too focused on looking for the next best-seller, causing companies to pass up opportunities to deliver important breakthroughs.
The Motley Fool April 29, 2005 Charly Travers	Value in Drug Stocks? Looking at some big pharma companies and liking what you see? Take a peek at biotech, too. GlaxoSmithKline... Pfizer... Amgen... Genzyme... etc.
The Motley Fool January 19, 2005 Stephen D. Simpson	Pfizer Doesn't Give Much Fizz The company reports mediocre earnings as investors remain nervous about the drug sector.
The Motley Fool February 28, 2005 Salim Haji	Why Value Trumps Growth Growth vs. value: This author works it out and comes up with a definitive answer. Obviously, the best possible investment is a combination -- buying a growth stock at a discount to intrinsic value.
Reason April 2005 Julian Sanchez	Soundbite: Behind the Curtain An interview with director Mike Wilson on his documentary Michael Moore Hates America, a Roger & Me spoof about Wilson's hunt for an interview with the zaftig progressive filmmaker.
The Motley Fool February 22, 2005 Charly Travers	Is Big Pharma a Bargain? While much of the drug sector is looking pretty tasty, Pfizer, with its attractive relative valuation, dominant marketing presence, and willingness to buy up blockbuster drugs, heads the list.
The Motley Fool February 22, 2005 Rich Duprey	Merger Mania Besets Japanese Pharmaceuticals A new law spurs megamergers in Japan's pharmaceutical industry. Stocks of companies seen as particularly interesting, including Eisai, Mitsubishi Pharma, and Shionogi, all jumped more than 2%.
The Motley Fool March 23, 2005 Chuck Saletta	Catching the Hot Potatoes Diversification can protect your portfolio from the worst of a company's stumbles.
The Motley Fool August 23, 2004 Ben McClure	Rethinking Big Pharma Risk is knocking Big Pharma stocks down. They won't be getting up anytime soon. Competition, soaring R&D costs, shifting business models, and political meddling combine to make drug stocks a riskier place to invest.
Reason January 2003 Brian Doherty	Tears of a Clown Michael Moore and the impotence of leftist politics
The Motley Fool May 6, 2004 Brian Gorman	Disney's Trap Disney's decision to block the release of Michael Moore's new film about the September 11 attacks and the Bush family's relationship with prominent Saudis plunges it into a political boondoggle.
The Motley Fool November 4, 2005 Rich Duprey	Merck Eases Its Pain The pharmaceutical giant wins an important Vioxx trial. And while it's a welcome reprieve for the company, the decision doesn't seem to warrant the enthusiasm with which the market greeted the decision.
The Motley Fool December 21, 2004 Seth Jayson	Buy Drug Fears? When headlines get bad, both value hunters and rule breakers should start feeling good about buying stock.
The Motley Fool April 21, 2004 Ben McClure	Discount Pharmacy With prices beaten down across the pharmaceuticals industry and the quarterly reporting season here, do any investment opportunities pop up?
Financial Advisor June 2005 Marla Brill	Fishing For Fallen Angels Putnam's David King shops for bargains among tarnished growth stocks.
The Motley Fool May 2, 2005 Chuck Saletta	The Value Investor's Triumvirate Companies with three critical strengths are ideal investment opportunities, if the price is right.
The Motley Fool February 8, 2008 Brian Orelli	Merck in Lukewarm Water The pharmaceutical's settlement ends a government probe into Medicaid overcharging allegations.
The Motley Fool March 1, 2006 Rich Duprey	Celebrex Doubles Lawsuit Risk A new study says the Pfizer painkiller doubles the risk of a heart attack. Investors, beware.
The Motley Fool November 8, 2004 Rick Aristotle Munarriz	Hitting a Moving Target The discount retailer readies its back-to-school quarterly report.
The Motley Fool April 11, 2007 Billy Fisher	A Replacement for Vioxx at Merck? Drug company has new pain medication in the pipeline. If Arcoxia is approved despite the long odds against it, it could payoff over the long run for Merck shareholders.
Pharmaceutical Executive July 1, 2005 Sarah Wealleans	Up in Smoke Pharma needs to learn a few lessons in how to respond when attacked. Maybe it's time to pay attention to the experience of an industry that's had more practice than anybody: tobacco.
The Motley Fool November 8, 2004 Brian Gorman	Pfizer's Gloom Factor The stock will continue to be depressed, but things will improve if Celebrex's safety is proven.
The Motley Fool December 8, 2004 Alyce Lomax	Eli Lilly Bares All The pharmaceutical publishes clinical trial results online. This is a step toward generating trust -- after all, shareholders, physicians, and consumers alike are likely looking askew at Big Pharma these days.
The Motley Fool January 7, 2010 Brian Orelli	Pfizer Strides Farther Into Generics Pfizer's new look might be just what the doctor ordered.
The Motley Fool May 10, 2005	Fair Value, Explained Don't confuse a stock's price with its fair value.
Pharmaceutical Executive March 1, 2007 Beth Herskovits	If I Ran Pfizer The industry is at a crossroads, and all eyes are on the world's largest drug maker. When Pfizer leads, others follow. So we asked: If you had that sort of influence, how would you steer Big Pharma?
The Motley Fool December 21, 2006 Ryan Fuhrmann	Dueling Fools: Merck Bear Rebuttal Yes, Merck is a good company, but investors can still do better.
The Motley Fool October 23, 2006 Brian Lawler	Merck Mints Money The pharmaceutical hangs on, despite ongoing Vioxx woes. Conservative investors may do best to stay away from Merck until a lower share-price opportunity presents itself, now that shares are no longer sporting such a large Vioxx discount.
BusinessWeek October 18, 2004 Catherine Arnst	The Waning of the Blockbuster Drug What's promising now are drugs that target niche diseases. That means painful restructuring ahead for Big Pharma
The Motley Fool December 28, 2004 W.D. Crotty	Pfizer: For Value Eyes Only While clearly not for conservative investors, this pharmaceutical deserves the attention of those looking for a value play.
The Motley Fool February 2, 2005 Brian Gorman	Pfizer's Troubling Trust Issue The company is in danger of losing the public's confidence.
The Motley Fool November 23, 2004 W.D Crotty	5 Drugs to Worry About? The recall of Merck's Vioxx raises concern among investors that there may be other pharmaceutical companies with potential legal exposure.
The Motley Fool May 13, 2005	When to Panic At what point, if a stock or the market is tanking, should you panic and think about selling?
The Motley Fool February 29, 2008 Brian Orelli	2007 Pharma Roundup How did big pharma do in 2007? With the drug sector earnings season winding down, now seems like a good time to take a look at how they fared and, more importantly, where they're headed.
The Motley Fool March 15, 2004 W.D. Crotty	60 Minutes on Drugs Will the weekly news magazine's prime-time slam rattle the drug stocks?
The Motley Fool July 7, 2004 Charly Travers	Pfizer Wants to Be Your Pfriend It seems that the pharmaceutical is limiting its profits in certain markets on its own terms in the hopes that concessions will be sufficient to keep from being handcuffed by Congress.
The Motley Fool September 7, 2004 Salim Haji	How Many Stocks Should You Own? Diversification into stocks you don't fully understand could increase risk within your portfolio.
The Motley Fool February 23, 2005 Stephen D. Simpson	Take Two on COX-2 FDA panel recommendations breathe new life into Merck and Pfizer's COX-2 pain medications. Looking ahead, investors should give a good, long look to the drug sector.
The Motley Fool October 25, 2005 Selena Maranjian	Is Biggest Best? Even giant companies can be volatile. Don't be complacent with blue chips. It's never smart to look at just one factor for any company. To have the best chance of doing well, you need to study a company closely, evaluating its health and prospects from many angles.
The Motley Fool June 23, 2005 Stephen D. Simpson	Dueling Fools: Merck Bear Looking at other big pharma peers, Merck is dead last when it comes to expected three- to five-year EPS growth. Why buy a troubled pharma when better options exist?
The Motley Fool September 30, 2008 Brian Orelli	Pharma, Cash, and You Pharma's been saving for a rainy day, and there's a thunderstorm outside.
The Motley Fool December 14, 2004 Chuck Saletta	Lift Your Lamp for Value It might not seem evident, but there's a strong parallel between Lady Liberty's call and an investor's search for value. Both are looking to accept others' discards.
The Motley Fool May 23, 2005 John Reeves	The Best Analyst Money Can Buy One of the keys to successful investing is knowledge. For other stocks that may or may not become value opportunities in the future, it would be ideal if you did your homework ahead of time. That way, you are ready when the situation arises.
The Motley Fool December 13, 2005 Rich Duprey	Merck's Bitter Pill The first federal Vioxx trial ends with a deadlocked jury, but that's not necessarily good news for the drugmaker, or investors.
The Motley Fool August 20, 2004 Paul Elliott	3 Inside Value Tips Find out where the "smart money" goes.